The tweet was deleted by the author.
But we saved everything 🙂.
Arcturus Therapeutics is set to present its latest research on ornithine transcarbamylase (OTC) deficiency at the Society for Inherited Metabolic Disorders (SIMD) 2026 Annual Meeting. The company is inviting attendees to visit Poster 52 to learn more about developments in its OTC deficiency program.
OTC deficiency is a rare genetic disorder that disrupts the urea cycle, posing serious health challenges. Arcturus Therapeutics's work in mRNA-based therapies targets these inherited metabolic diseases and represents an ongoing commitment to advancing the field. Further details of the program and research will be available at the conference.